Announced
Synopsis
AOP Health International Management, a European pioneer in integrated therapies for rare diseases and in critical care, agreed to acquire the remaining shares in Shield Therapeutics, a patient-focused, commercial-stage pharmaceutical company, for £33.5m. AOP and Shield have entered into the Relationship Agreement pursuant to which AOP has agreed amongst other things to permit Shield to continue to be able to operate independently of AOP.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite
Seller Team (2)
Bidder Team (10)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy